Related Experiment Videos
Adoptive immunotherapy prevents prostate cancer in a transgenic animal model
L Granziero1, S Krajewski, P Farness
1The R.W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121, USA.
Abstract:
Cancer-related mortality can be decreased by prevention, early detection and improved therapies. Although animal models should be used to evaluate the success of cancer therapies, their usefulness is controversial. Many cancer therapies that have cured tumors in mice have not met with similar success when attempted in humans. Current animal models rely mainly on inoculating cell lines into animals, a method that does not reproduce the natural development of the tumor, both for the kinetics of induction and the anatomical site concerned. In this study, we have used an SV40 T-antigen-transgenic mouse model of prostate cancer in which the tumor spontaneously develops orthotopically with a disease progression that closely resembles the progression of human prostate cancer. We have used this model to test the suitability of adoptive cellular immunotherapy. Transfer of naive cells obtained from a T-antigen-negative congenic animal had significant but partial effects: it prevented development of malignant tumors, leaving just minor foci of residual tumor and/or hyperplasia. Adoptive transfer of memory lymphocytes specific for T-antigen, which is a prostatic self antigen in this model, prevented tumor development and progression without affecting the morphology and function of involved tissues. Treated animals were able to breed, and their survival was greatly increased. These results strongly suggest that adoptive immunotherapy should be successful in treating early stages of human prostate cancer.
Insights
Adoptive immunotherapy using T-antigen specific memory lymphocytes shows promise for early-stage prostate cancer. This approach prevented tumor development and increased survival in a mouse model, suggesting potential for human treatment.
Area of Science:
- Oncology
- Immunology
- Translational Medicine
Background:
- Current animal models for cancer therapy evaluation have limitations in mimicking human disease progression.
- Many promising cancer therapies in mice fail in human clinical trials due to model discrepancies.
Purpose of the Study:
- To evaluate adoptive cellular immunotherapy in a novel orthotopic mouse model of prostate cancer.
- To assess the efficacy of transferring naive cells versus antigen-specific memory lymphocytes.
Main Methods:
- Utilized a spontaneously developing, orthotopic SV40 T-antigen-transgenic mouse model of prostate cancer.
- Administered adoptive transfer of either naive congenic cells or T-antigen-specific memory lymphocytes.
- Monitored tumor development, progression, tissue morphology, and animal survival.
Main Results:
- Transfer of naive cells partially prevented malignant tumor development, leaving residual tumor foci.
- Adoptive transfer of T-antigen-specific memory lymphocytes completely prevented tumor development and progression.
- Treated animals maintained normal tissue function, could breed, and exhibited significantly increased survival.
Conclusions:
- The developed mouse model closely mimics human prostate cancer progression, offering a more relevant platform for therapy testing.
- Adoptive immunotherapy with antigen-specific memory lymphocytes is a viable strategy for treating early-stage prostate cancer.
- This approach holds significant potential for improving outcomes in human prostate cancer patients.